Tech Company Financing Transactions

Noema Pharma Funding Round

On 12/11/2024, Noema Pharma raised Series B funding from EQT Life Sciences.

Transaction Overview

Company Name
Announced On
12/11/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Proceeds Purpose
The company intends to use the funds to support its four active Phase 2 trials, with key data readouts anticipated in 2025, including additional development activities for basimglurant (NOE-101), an mGluR5 negative allosteric modulator currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC); gemlapodect (NOE-105), a PDE10a inhibitor in a Phase 2b trial for Tourette syndrome and under development for childhood-onset fluency disorder (COFD or stuttering); and NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and other symptoms of menopause.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Barfüsserplatz 3
Basel, 4051
CH
Phone
Undisclosed
Email Address
Overview
Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema's research and development is focused on understanding and meeting patient needs using our novel therapies.
Profile
Noema Pharma LinkedIn Company Profile
Social Media
Noema Pharma Company Twitter Account
Company News
Noema Pharma News
Facebook
Noema Pharma on Facebook
YouTube
Noema Pharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
George Garibaldi
  George Garibaldi LinkedIn Profile  George Garibaldi Twitter Account  George Garibaldi News  George Garibaldi on Facebook
Chief Financial Officer
Michael Gutch
  Michael Gutch LinkedIn Profile  Michael Gutch Twitter Account  Michael Gutch News  Michael Gutch on Facebook
Co-Founder
Luigi Costa
  Luigi Costa LinkedIn Profile  Luigi Costa Twitter Account  Luigi Costa News  Luigi Costa on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/11/2024: Flare venture capital transaction
Next: 12/11/2024: TrueWind venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary